Shingrix (herpes zoster vaccine) licensed in UK for prevention of shingles in adults aged 50 years and older as well as in adults 18 years of age or older who are at increased risk of shingles
As of 1 Sept 2021, it will be available via current national shingles immunisation programme for patients aged 70 to 79 years who are eligible for shingles vaccination but are clinically contraindicated to receive current vaccine on the programme due to being immunocompromised.
Source:
PharmaTimes
Resource links:
SPS commentary:
A joint letter from Public Health England and NHSE/I sets out the details of the introduction of the Shingrix® vaccine for immunocompromised individuals from 1 September 2021.
A PGD template supports the administration of Shingrix® vaccine for immunocompromised individuals in accordance with the national shingles immunisation programme.